↓ Skip to main content

Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond

Overview of attention for article published in Seminars in Respiratory & Critical Care Medicine, February 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
138 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Published in
Seminars in Respiratory & Critical Care Medicine, February 2015
DOI 10.1055/s-0034-1397040
Pubmed ID
Authors

Natasha Holmes, Steven Tong, Joshua Davis, Sebastiaan Hal

Abstract

There has been a welcome increase in the number of agents available for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin remains an acceptable treatment option, with moves toward individualized dosing to a pharmacokinetic/pharmacodynamic (PK/PD) target. Numerous practicalities, however, would need to be resolved before implementation. Lipoglycopeptides as a class show excellent in vitro potency. Their long half-lives and complex PKs may preclude these agents being used in critically ill patients. Anti-MRSA cephalosporins provide great promise in the treatment of MRSA. These agents, despite broad-spectrum activity, should be reserved for patients with MRSA infections as it is likely that usage will be associated with increased rates of resistance. Daptomycin is currently the only antibiotic to have shown noninferiority to vancomycin in the treatment of MRSA bacteremia. The results of an open-labeled trial to address the superiority of daptomycin compared with vancomycin in reduced vancomycin susceptibility infections are eagerly anticipated. No drug to date has shown superiority to vancomycin in the treatment of MRSA infections with the possible exception of linezolid in hospital-acquired pneumonia (HAP), making linezolid an important option in the treatment of MRSA-proven HAP. Whether these strengths and features are agent or class specific are unclear but will likely be answered with the marketing of tedizolid. There are insufficient data to recommend either quinupristin/dalfopristin or tigecycline, as first line in the treatment of severe MRSA infections. These agents however remain options in patients with no other alternatives.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 <1%
India 1 <1%
Czechia 1 <1%
Argentina 1 <1%
Japan 1 <1%
Unknown 133 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 21 15%
Student > Bachelor 18 13%
Researcher 17 12%
Student > Postgraduate 14 10%
Student > Doctoral Student 12 9%
Other 38 28%
Unknown 18 13%
Readers by discipline Count As %
Medicine and Dentistry 49 36%
Pharmacology, Toxicology and Pharmaceutical Science 16 12%
Biochemistry, Genetics and Molecular Biology 15 11%
Agricultural and Biological Sciences 12 9%
Immunology and Microbiology 4 3%
Other 11 8%
Unknown 31 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2016.
All research outputs
#6,948,708
of 12,359,797 outputs
Outputs from Seminars in Respiratory & Critical Care Medicine
#165
of 321 outputs
Outputs of similar age
#111,825
of 265,723 outputs
Outputs of similar age from Seminars in Respiratory & Critical Care Medicine
#5
of 12 outputs
Altmetric has tracked 12,359,797 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 321 research outputs from this source. They receive a mean Attention Score of 2.5. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,723 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.